Detalles de la búsqueda
1.
Long-term efficacy and safety of tucidinostat in patients with relapsed or refractory peripheral T-cell lymphoma: final analysis of phase IIb results.
Haematologica
; 2024 Jun 06.
Artículo
Inglés
| MEDLINE | ID: mdl-38841789
2.
Oral HDAC inhibitor tucidinostat in patients with relapsed or refractory peripheral T-cell lymphoma: phase IIb results.
Haematologica
; 108(3): 811-821, 2023 03 01.
Artículo
Inglés
| MEDLINE | ID: mdl-36200417
3.
Oral histone deacetylase inhibitor tucidinostat (HBI-8000) in patients with relapsed or refractory adult T-cell leukemia/lymphoma: Phase IIb results.
Cancer Sci
; 113(8): 2778-2787, 2022 Aug.
Artículo
Inglés
| MEDLINE | ID: mdl-35579212
4.
Oral histone deacetylase inhibitor HBI-8000 (tucidinostat) in Japanese patients with relapsed or refractory non-Hodgkin's lymphoma: phase I safety and efficacy.
Jpn J Clin Oncol
; 52(9): 1014-1020, 2022 Sep 18.
Artículo
Inglés
| MEDLINE | ID: mdl-35649345
5.
The epigenetic immunomodulator, HBI-8000, enhances the response and reverses resistance to checkpoint inhibitors.
BMC Cancer
; 21(1): 969, 2021 Aug 30.
Artículo
Inglés
| MEDLINE | ID: mdl-34461854
6.
Induction of apoptosis by HBI-8000 in adult T-cell leukemia/lymphoma is associated with activation of Bim and NLRP3.
Cancer Sci
; 107(8): 1124-33, 2016 Aug.
Artículo
Inglés
| MEDLINE | ID: mdl-27193821
7.
HBI-8000, HUYABIO Lead Clinical Program, Is a Selective Histone Deacetylase Inhibitor With Therapeutic Benefits in Leukemia and in Solid Tumors.
Front Oncol
; 11: 768685, 2021.
Artículo
Inglés
| MEDLINE | ID: mdl-35070972
Resultados
1 -
7
de 7
1
Próxima >
>>